International: +1-347-960-6455
Hospital Acquired Pneumonia (HAP) Therapeutics - Pipeline Analysis 2018

Hospital Acquired Pneumonia (HAP) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10063 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Infectious
Select License Type

Hospital acquired pneumonia (HAP) is a lung infection that occurs during hospital stay. HAP can spread via health care workers, who may pass germs from their hands or clothes from one patient to another. This is why hand-washing, wearing gowns, and using other safety measures is so important in hospitals and other healthcare settings. It has been observed that HAP may develop at least 48 hours after hospital admission. There are several risk factors associated with HAP including alcohol consumption, major surgery, weak immune system, chronic lung disease, and swallowing problems. The disease can be treated with antibiotics and can be controlled by taking hygiene prevention during a hospital stay. Arsanis Inc. is in the process of developing ASN100 as a monoclonal antibody for the treatment of HAP. Some of the companies involved in HAP pipeline are Allecra Therapeutics GmbH and Nabriva Therapeutics plc among others.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.